Eli Lilly Doubles Down on AI: Is the Stock a Buy?
ByAinvest
Sunday, Jan 18, 2026 3:03 am ET1min read
LLY--
NVDA--
Eli Lilly is partnering with Nvidia to build an AI research lab, doubling down on its AI efforts. The drugmaker has made several AI moves in recent years, including launching TuneLab, a platform for an AI drug-discovery model. While the company's AI-related efforts are unlikely to pay off soon, it seems well-positioned to benefit from the transformation of drug discovery if AI proves effective. There are other reasons to buy the stock, including its strong financial performance and growing dividend.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet